logo BDSP

Base documentaire

  1. Reverse transcriptase-polymerase chain reaction assays for prostate cancer : Prostate-specific antigen : the best prostatic tumor marker.

    Fascicule - En anglais

    The use of reverse transcriptase-polymerase chain reaction assays (RT-PCR) directed against prostate or prostate cancer-specific genes is a controversial topic.

    This article reviews the field thoroughly to delineate areas where consensus may have been reached versus those areas of continuing controversy.

    Regardless of the tissue substrate tested (blood, marrow), there is apparent consensus that patients without cancer have negative assays.

    There is additional consensus supporting that untreated patients with metastatic disease have positive assays.

    At least three groups have shown that RT-PCR assays of prostate-specific antigen mRNA provide unique prognostic information in the patients with clinically localized disease.

    There is continuing controversy of whether RT-PCR directed against any marker gene is of value in staging prostate cancer.

    Mots-clés Pascal : Adénocarcinome, Prostate, Marqueur tumoral, Antigène spécifique prostate, Dépistage, Dosage, Réaction chaîne polymérase, Transcription inverse, Technique, Erreur, Effet biologique, Intervention, Etude statistique, Revue bibliographique, Homme, Tumeur maligne, Appareil urinaire pathologie, Appareil génital mâle pathologie, Prostate pathologie, Biologie, Biologie moléculaire

    Mots-clés Pascal anglais : Adenocarcinoma, Prostate, Tumoral marker, Prostate specific antigen, Medical screening, Assay, Polymerase chain reaction, Reverse transcription, Technique, Error, Biological effect, Operation, Statistical study, Bibliographic review, Human, Malignant tumor, Urinary system disease, Male genital diseases, Prostate disease, Biology, Molecular biology

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0288320

    Code Inist : 002B14D02. Création : 15/07/1997.